KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study. PMID 40051286 · J Gynecol Oncol · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study. PMID 40049418 · J Thromb Haemost · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial. PMID 40048558 · J Urol · 2025-Jul Eligible study characteristics (oncology, human, phase 3, drug intervention, original results) are present, but it is excluded because it is a single-arm trial (non-randomized) and its primary/key outcome is a patient-reported perception/acceptability endpoint, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or an endpoint analyzed with Kaplan-Meier or HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. PMID 40045918 · J Eur Acad Dermatol Venereol · 2025-Jul The study is a Phase III randomized controlled trial of a drug intervention (deucravacitinib) in humans with original results. However, it is not an oncology study, as it investigates plaque psoriasis, a non-malignant inflammatory skin disease. Furthermore, the primary and key secondary efficacy endpoints reported are response rates (PASI 90, PGA, DLQI), not time-to-event outcomes such as OS, PFS, DFS, etc., nor do they include Kaplan-Meier curves or hazard ratios for such endpoints. Therefore, it fails the required criteria for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of carvedilol on the prevention of cardiotoxicity induced by anthracyclines: Design and rationale of the CARDIOTOX trial. PMID 39988204 · Am Heart J · 2025-Jul This is a clinical trial protocol for a randomized, double-blind, placebo-controlled trial (CARDIOTOX) evaluating carvedilol for prevention of cardiotoxicity in cancer patients receiving anthracyclines. While it is an oncology, human, randomized trial with a drug intervention, it fails multiple eligibility criteria: (1) The phase is not specified as Phase III/IIIb or Phase II/III; it is a protocol, not a result report. (2) The primary endpoint is a composite of cardiac events and echocardiographic changes at 12 months, not a standard oncology time-to-event efficacy endpoint like OS, PFS, DFS, etc. (3) It is a protocol without results, not an original result report. Therefore, it is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Electroacupuncture Reduces Duration of Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Randomized Trial. PMID 39978558 · Gastroenterology · 2025-Jul 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR -1, -2, and -3, in Patients with Refractory Metastatic Colorectal Cancer. PMID 39969131 · J Clin Pharmacol · 2025-Jul The study is a population pharmacokinetic analysis of fruquintinib using data from Phase I/Ib and the Phase III FRESCO-2 study. It does not report primary or key secondary time-to-event efficacy endpoints (OS, PFS, etc.) or associated statistical results (Kaplan-Meier, HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of White Light With Narrow Band Imaging Using Flexible Laryngoscopy for the Detection of Local Recurrences After (Chemo)Radiation for Pharyngeal or Laryngeal Cancer: A Randomised Controlled Trial. PMID 39952630 · Clin Otolaryngol · 2025-Jul The record describes a randomized controlled trial in oncology with time-to-event endpoints, but it lacks a drug-containing intervention (it compares diagnostic imaging modalities) and does not explicitly report a Phase III/IIIb or Phase II/III trial phase. Therefore, it does not meet all required eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial. PMID 39929333 · J Thorac Oncol · 2025-Jul The record is a randomized, placebo-controlled trial in human oncology with drug intervention and primary time-to-event endpoints. However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types). The 'phase3_or_definitive' criterion cannot be established, making overall eligibility uncertain.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Prognostic significance of para-aortic node metastasis in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis. PMID 39924672 · J Gynecol Oncol · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Single versus multiple fraction stereotactic spine radiosurgery for spinal metastases: a prospective randomized Phase II trial. PMID 39894278 · Spine J · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Low-cost interventions to increase uptake of cervical cancer screening among emergency department patients: Results of a randomized clinical trial. PMID 39873883 · Acad Emerg Med · 2025-Jul The study is a randomized clinical trial in human oncology (cervical cancer screening), but it is excluded because it lacks a drug-containing intervention (the intervention is low-cost behavioral interventions: basic referral and text messaging) and the primary endpoint is screening uptake (a categorical, binary outcome at a fixed time point), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or any analysis using Kaplan-Meier or hazard ratios).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Psychological Factors on Survival in Metastatic Esophagogastric Cancer: Secondary Analysis of a Randomized Controlled Trial. PMID 39808755 · JCO Oncol Pract · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The Screening Tomosynthesis Trial with Advanced Reader Methods (STREAM): design and rationale of a population-based breast cancer screening trial. PMID 39786515 · Eur Radiol · 2025-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Increased acute-phase reaction after the transoral endoscopic thyroidectomy vestibular approach (TOEVA) compared with minimally invasive video-assisted thyroidectomy (MIVAT) for unilateral thyroidectomy. PMID 39753907 · Surg Today · 2025-Jul The study is a randomized trial on human thyroid cancer (oncology, human, randomized, primary results), but it does not meet eligibility because it compares surgical techniques (non-drug intervention) and lacks a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR analysis. The primary outcomes are inflammatory biomarkers and recovery metrics.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials. PMID 38978352 · Mol Oncol · 2025-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical Efficacy of Bevacizumab Combined with Temozolomide in Treating Gliomas. PMID 38758157 · Altern Ther Health Med · 2025-Jul Eligibility cannot be established because the trial phase is not explicitly confirmed in the provided record, which is a mandatory requirement for inclusion in this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis. PMID 39891102 · BMC Cancer · 2025-Jan-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Statistical analysis plan for a pragmatic randomised controlled trial comparing enhanced acceptance and commitment therapy plus ( +) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial. PMID 39881331 · Trials · 2025-Jan-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin. PMID 39881222 · BMC Cancer · 2025-Jan-29 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Remote symptom monitoring with patient-reported outcomes and nudges during lung cancer immunotherapy in China (PRO-NET): protocol for a randomised controlled trial. PMID 39880457 · BMJ Open · 2025-Jan-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane. PMID 39875951 · Cardiooncology · 2025-Jan-28 This is a protocol/design article for an ongoing Phase III randomized trial in oncology with a drug intervention. However, it reports no efficacy results. The primary endpoint (incidence of cardiac dysfunction) is a safety/toxicity endpoint, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required. Therefore, it is excluded as a protocol without results.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exercise medicine as adjunct therapy during RADIation for CAncer of the prostaTE to improve treatment efficacy - protocol for the ERADICATE study: a phase II randomised controlled trial. PMID 39875858 · BMC Cancer · 2025-Jan-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma. PMID 39875173 · J Immunother Cancer · 2025-Jan-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial. PMID 39492713 · Circulation · 2025-Jan-28 The record describes a randomized controlled trial in humans undergoing stem cell transplantation for hematologic malignancies, but it is a non-drug intervention (exercise therapy). The primary endpoints are cardiopulmonary fitness and exercise cardiac function, not time-to-event efficacy (e.g., OS, PFS). Phase is not definitively established as III/IIIb or II/III. Therefore, it does not meet the eligibility criteria for a drug-containing intervention trial with a primary time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
One-stage versus two-stage video-assisted thoracic surgery for synchronous bilateral pulmonary nodules: protocol for a single center, non-randomized clinical trial (OTVATS-1). PMID 39871205 · BMC Surg · 2025-Jan-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study. PMID 39871169 · BMC Cancer · 2025-Jan-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pharmacokinetics and pharmacodynamics of ciprofol after continuous infusion in elderly patients. PMID 39871139 · BMC Anesthesiol · 2025-Jan-27 Study is a randomized, controlled trial in oncology patients (undergoing gastrointestinal tumor resection) evaluating a drug (ciprofol vs propofol). However, it is not a Phase III/IIIb or Phase II/III trial (no phase specified, appears to be a pharmacokinetic/efficacy study), and it lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer. PMID 39865083 · NPJ Breast Cancer · 2025-Jan-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial. PMID 39856583 · BMC Cancer · 2025-Jan-24 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. PMID 39432738 · Br J Dermatol · 2025-Jan-24 The report describes a randomized trial of a drug (ritlecitinib) for alopecia areata, which is an autoimmune disorder, not a malignant neoplasm. The efficacy endpoints are not time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates. PMID 39568595 · RSC Med Chem · 2025-Jan-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
[Application Research of Narrative Care to the Management of Symptom Clusters and Post-traumatic Growth in Patients Undergoing Lung Cancer Surgery]. PMID 39988438 · Zhongguo Fei Ai Za Zhi · 2025-Jan-20 The study is a randomized controlled trial in human lung cancer surgery patients, but it evaluates a non-drug nursing intervention (narrative care) for symptom clusters and post-traumatic growth, not a drug-containing intervention. It reports only patient-reported outcome measures (anxiety, sleep, quality of life, post-traumatic growth) at specific time points, without any time-to-event efficacy endpoints. The trial phase is not specified in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. PMID 39833722 · BMC Cancer · 2025-Jan-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: study protocol for a randomised controlled trial. PMID 39832986 · BMJ Open · 2025-Jan-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A comparative study between central quadrantectomy and nipple resection with areola preservation Versus Grisotti flap mammoplasty in central breast lesions extending to nipple: a randomized clinical trial. PMID 39828867 · J Egypt Natl Canc Inst · 2025-Jan-20 The study is an oncology randomized trial with primary results, but it does not meet the eligibility criteria because it lacks a specified Phase III/II/IIIb designation, involves a non-drug (surgical) intervention only, and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. PMID 39432867 · J Clin Oncol · 2025-Jan-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Artificial Intelligence for Adenoma and Polyp Detection During Screening and Surveillance Colonoscopy: A Randomized-Controlled Trial. PMID 39860586 · J Clin Med · 2025-Jan-17 The study is excluded because it is not a drug intervention trial (it compares an AI-assisted colonoscopy system to standard colonoscopy) and does not report a time-to-event efficacy endpoint required for Kaplan-Meier digitization. While it is an oncology-related RCT in humans, it fails the key criteria of drug intervention and time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. PMID 39846984 · Oncologist · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial. PMID 39693892 · Eur J Cancer · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. PMID 39576210 · Clin Cancer Res · 2025-Jan-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial. PMID 39389757 · Gut · 2025-Jan-17 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
A Community Health Worker-driven and integrated interactive text messaging intervention to promote smoking cessation and lung cancer screening uptake rates among high-risk Asian immigrants: a feasibility pilot RCT study. PMID 40471875 · Transl Behav Med · 2025-Jan-16 The study is a randomized feasibility pilot of a behavioral and community health intervention for smoking cessation and lung cancer screening uptake. It is not a Phase III/IIIb or Phase II/III drug intervention trial, and it does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS) with Kaplan-Meier analysis or hazard ratio. The focus is on feasibility, acceptability, and process outcomes (e.g., screening completion rates), not a definitive efficacy trial for a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Supporting community translation of lung cancer screening: A web-based decision aid to support informed decision making. PMID 39817729 · Transl Behav Med · 2025-Jan-16 The study is a randomized feasibility/acceptability trial of a decision aid for lung cancer screening. While oncology-related and randomized, it is not a Phase III/IIIb or Phase II/III trial with a drug intervention and a primary time-to-event efficacy endpoint (e.g., OS, PFS). The primary outcomes are feasibility metrics, not survival or progression endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Continuous Infusion Therapy With Low-dose Terlipressin Combined With Norepinephrine on Hemodynamics, Inflammatory Markers, and Prognosis in Patients With Severe Septic Shock. PMID 39091078 · Mil Med · 2025-Jan-16 The study is a randomized trial with drug interventions and original results, but it is not an oncology study and does not report a primary time-to-event efficacy endpoint (e.g., overall survival, progression-free survival).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors. PMID 39810144 · World J Surg Oncol · 2025-Jan-15 The record describes a randomized study of a TPO receptor agonist and platelet transfusion for chemotherapy-induced thrombocytopenia in cancer patients. While it is a randomized, oncology-related, human study with a drug intervention (avatrombopag) and reports original results, it fails two key eligibility criteria. First, the phase is not specified as Phase III/IIIb or Phase II/III; the publication type 'Randomized Controlled Trial' does not establish a definitive phase, and no phase is mentioned in the title, abstract, or metadata. Second, the primary endpoints are platelet counts, recovery times, cytokine levels, and coagulation indices—all short-term, laboratory-based outcomes. There is no mention of a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier analysis or hazard ratio for a time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment. PMID 39809874 · NPJ Digit Med · 2025-Jan-14 The study is a randomized Phase III trial in oncology, but the intervention is non-drug (digital integrative medicine) and the endpoints are symptom/quality-of-life measures and healthcare utilization, not time-to-event efficacy outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line systemic therapy and sequencing options in advanced biliary tract cancer: A systematic review and network meta-analysis. PMID 39647857 · Biosci Trends · 2025-Jan-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Young, Empowered & strong (YES): a study protocol paper for a randomized controlled trial of an mHealth symptom monitoring and self-management intervention for adolescent and young adult (AYA) breast cancer survivors. PMID 39799291 · BMC Public Health · 2025-Jan-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Phase III Evaluation of Treatment Combinations in Three-Arm Trials. PMID 39467219 · J Clin Oncol · 2025-Jan-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -